View Our Facilities
In The News
BioCytics Successfully Completes a Key Regulatory Milestone with Recent FDA INTERACT Meeting
BioCytics INTERACT Meeting – 11/18/25
Huntersville, NC, November 18, 2025—BioCytics is pleased to announce they successfully reached a regulatory milestone for de-risking clinical development plans with a productive FDA INTERACT meeting during which they discussed manufacturing immune cell therapies at the point of care.
Dr. Powderly Discusses TILs and Cell and Gene Therapy on the “TIL Talks” Podcast
TIL Talks by Chris White – 7/28/25
Listen to Dr. Powderly as he talks with podcast host Chris White about advancements in immunotherapy, with a focus on Peripheral Tumor Infiltrating Lymphocytes (TILs) and their potential for use in cancer treatment. Chris White is a Mucosal Melanoma survivor who has created the podcast called “TIL Talks”, in which he holds one-on-one conversations with patient recipients, caregivers, and industry leaders who have experienced first-hand the curative possibilities of TILs and/or cell and gene therapies. Over the next few months, Dr. Powderly and Chris White will engage in a total of four conversations.
You can hear the first one on YouTube or Spotify using the links below. Look for Episode #12. Then, come back to our News section over the next few weeks to access new links as the next interviews get released.
In this first session, Dr. Powderly discusses his experience as an oncologist and the efforts and clinical trials that are ongoing at Carolina BioOncology. He and Chris then discuss the importance of cell therapy and the need for expanded access to clinical trials. They also highlight the importance of patient advocacy and patients being active in their own care efforts. Finally, they discuss the future of cancer therapies.
BioCytics Partners on NCInnovation-Funded Vaccine Preservation Project
Inside UNC Charlotte – 5/14/25
BioCytics is proud to serve as a subawardee on a newly funded NCInnovation project led by Dr. Susan Trammell at UNC Charlotte. The research is one of 17 projects selected statewide and focuses on Light-Assisted Drying (LAD), a novel laser technology enabling room-temperature storage of vaccines and biologics by eliminating cold chain requirements. BioCytics will evaluate LAD’s potential to preserve cell therapy reagents, antibodies, and biospecimens, with proof-of-concept work using our GMP-grade materials and IRB-approved human samples.
AABB-Accredited Facility Biotherapies Services Spotlight Series February 2025: Carolina BioOncology Institute
AABB – 2/1/25
In 2005, John Powderly, MD, founded both CBOI and BioCytics as reflections of the same vision to deliver autologous immune cell therapies manufactured at the point of care for early phase clinical trials. He states that, “We believe the future of bespoke regenerative medicine depends upon regional human application labs as an efficient, affordable and accessible delivery system. Our recent AABB accreditation is another step closer to realizing our vision to enable future cellular immune cures for solid tumor cancer patients.”
